Emulsified composition for dilution and cancer vaccine composition

A cancer vaccine composition comprising:

• A) an ester of a fatty acid having 8 to 22 carbon atoms and an alcohol having 2 to 24 carbon atoms, the solidification point of the ester being not more than 10° C., at 30 to 80% by weight;
• B) a nonionic surfactant consisting of a hydroxy fatty acid triglyceride adduct with 5 to 20 mol of ethylene oxide, at 0.5 to 20% by weight;
• C) an emulsifier that is a partial ester of a polyhydric alcohol and a fatty acid, the partial ester being liquid at 40° C., at 0 to 20% by weight;
• and
• E) a water phase comprising a cancer antigen peptide having 8 to 12 amino acids or a dimer thereof, at 10 to 60% by weight;
• wherein the composition is a W/O emulsion.

A specific cytotoxic T cell inducer comprising:

• A) an ester of a fatty acid having 8 to 22 carbon atoms and an alcohol having 2 to 24 carbon atoms, the solidification point of the ester being not more than 10° C., at 30 to 80% by weight;
• B) a nonionic surfactant consisting of a hydroxy fatty acid triglyceride with 5 to 20 mol of ethylene oxide added thereto, at 0.5 to 20% by weight;
• C) an emulsifier that is a partial ester of a polyhydric alcohol and a fatty acid, the partial ester being liquid at 40° C., at 0 to 20% by weight;
• and
• E) a water phase comprising a cancer antigen peptide having 8 to 12 amino acids or a dimer thereof, at 10 to 60% by weight;
• wherein the composition is a W/O emulsion.